TCT-556 One-year Outcome of a Prospective Trial Stopping Dual Antiplatelet Therapy at 3-Month after Everolimus-eluting Cobalt-chromium Stent Implantation: ShortT and OPtimal duration of Dual AntiPlatelet Therapy after everolimus-eluting cobalt-chromium stent (STOPDAPT) trial

Masahiro Natsuaki,Takeshi Morimoto,Erika Yamamoto,Hiroki Shiomi,Yutaka Furukawa, Mitsuru Abe,Koichi Nakao,Tetsuya Ishikawa,Kazuya Kawai,Kei Yunoki,Shogo Shimizu,Masaharu Akao,Shinji Miki,Masashi Yamamoto,Hisayuki Okada,Kozo Hoshino,Kazushige Kadota,Yoshihiro Morino,Keiichi Igarashi,Kengo Tanabe

Journal of the American College of Cardiology（2015）

引用 0|浏览0

暂无评分

摘要

Prolonged dual antiplatelet therapy (DAPT) after coronary stent implantation is associated with higher risk for bleeding. Second-generation drug-eluting stents (G2-DES), cobalt-chromium everolimus-eluting stent (CoCr-EES) in particular, are reported to have lower risk for stent thrombosis (ST)

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要